Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

NCT07470853 is registered in ClinicalTrials.gov with Whitehawk Therapeutics, Inc. as lead sponsor.

NCT NCT07470853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07470853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Lead sponsor
Whitehawk Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 15, 2026
Completion date
February 29, 2028
Enrollment
265 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, platinum resistant ovarian cancer, proc